Supplemental conventional transarterial embolization/chemoembolization therapy via extrahepatic arteries for hepatocellular carcinoma

Autor: Jianfei Tu, Yuanqan Huang, Guomin Jiang, Zhongzhi Jia, Feng Tian, Tao Shen
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Adult
Male
medicine.medical_specialty
Carcinoma
Hepatocellular
Organoplatinum Compounds
Cystic artery
Gastroenterology
lcsh:RC254-282
030218 nuclear medicine & medical imaging
03 medical and health sciences
Extrahepatic artery
0302 clinical medicine
Internal medicine
medicine.artery
medicine
Carcinoma
Humans
Radiology
Nuclear Medicine and imaging
Chemoembolization
Therapeutic
Transcatheter arterial chemoembolization
Survival rate
Aged
Epirubicin
Aged
80 and over
business.industry
Liver Neoplasms
Arteries
General Medicine
hepatocellular carcinoma
Middle Aged
Inferior phrenic arteries
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Adrenal artery
Oxaliplatin
Survival Rate
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Female
alpha-Fetoproteins
Radiology
Tomography
X-Ray Computed
business
Artery
transcatheter arterial chemoembolization
Zdroj: Journal of Cancer Research and Therapeutics, Vol 13, Iss 4, Pp 720-724 (2017)
ISSN: 1998-4138
0973-1482
Popis: Purpose: To assess the value of conventional transarterial embolization/chemoembolization (cTAE/TACE) therapy via extrahepatic arteries for patients with unresectable hepatocellular carcinoma (HCC). Methods: Patients with unresectable HCC who underwent cTAE/TACE therapy via extrahepatic arteries between May 2008 and July 2016 across 4 medical centers were identified. The technical success, serum alpha-fetoprotein (AFP) levels changes, tumor response, disease control rate, survival rate, and major complication were analyzed. Results: A total of 185 patients (167 male and 18 female) were included in this study. A total of 401 procedures were performed of the 185 patients, with 2.2 ± 0.4 procedures for each patient. A total of 197 extrahepatic arteries were identified, including inferior phrenic artery (n = 80), omental artery (n = 39), gastric artery (n = 22), right renal capsular artery (n = 21), adrenal artery (n = 13), cystic artery (n = 11), and right internal mammary artery (n = 11). The technical success rate was 96.8% (179/185). The serum AFP levels were significantly reduced at 1 month after treatment in 71 patients whose AFP ≥400 ng/mL preprocedure (P < 0.01). The disease control rate was 93% (172/185) at 3 months after cTAE/TACE, with partial response, stable disease, or progressive disease of 115, 57, and 13 patients, respectively. The cumulative survival rate from the time of cTAE/TACE via extrahepatic arteries was 100% at 6 months. There were no embolization-related major complications. Conclusion: cTAE/TACE therapy via the extrahepatic arteries can reduce the incidence of presence of residual HCC, and improve the therapeutic efficacy of cTAE/TACE.
Databáze: OpenAIRE
Externí odkaz: